



Commercial/Healthcare Exchange PA Criteria

Effective: May 2004

Prior Authorization: Testosterone

Products Affected: Androgel, Androderm, Android, Fortesta, Methyltestosterone, Natesto, Striant, Testim, Testoderm, Testopel, Testosterone Cream (brand name only), Vogelxo, Xyosted

Covered Uses:

1. Primary hypogonadism (congenital or acquired)
2. Hypogonadotropic hypogonadism (congenital or acquired)

Exclusion Criteria:

1. Sexual dysfunction, per pharmacy rider
2. Use in fatigue, malaise, depression and other non-specific and non-FDA approved uses

Required Medical Information:

1. Diagnosis
2. Baseline total testosterone lab result
3. Past medication trials

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 Months*

* Authorizations for **Aveed** will be granted for 4 IM injections over 6 months (week 0, week 4, and then every 10 weeks). Subsequent approvals will be granted for injections every 10 weeks

* Authorizations for **Testopel** will be granted for 2 implants over 1 year. Additional implants may be approved with documented need.

Other Criteria: ConnectiCare considers **Androgel** to be medically necessary in males when the following criteria is met:

1. Patient has a lack of testosterone, due to injury, surgery, trauma, tumor, radiation to the pituitary, or bilateral cryptorchidism, torsion, or infection; confirmed by the below:
 - a. Total testosterone level <240 ng/ LH, FSH, and prolactin L (for patients with a BMI >29 a free testosterone level must also be measured) - a copy of lab must be provided
- OR**
2. Use in treatment of male osteoporosis with objective data (BMD results) that support use, in association with hypotestosterone levels;
- OR**
3. Member has gender dysphoria or undergoing gender reassignment surgery and is concomitantly receiving mental health services.

Last Res. November 13th, 2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.



AND

4. For all other testosterone products: patient must have had an intolerance to, or treatment failure of **AndroGel**

References:

1. Facts and Comparisons Online

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	5/2004
2	Policy Revision	Updated Template from CCI to EH CCI P&T Review History:3/04, 6/07, 6/08, 9/09, 9/10, 4/11, 12/11, 10/12, 10/13, 10/14, 11/15, 2/16, 2/17, 5/17, 1/18 CCI Revision Record:12/08, 4/11, 5/12, 10/13, 1/14, 4/14, 6/14, 12/14, 10/15, 2/17, 5/17, 1/18, 1/19	All	4/25/2019
3	Policy Update	Removed Aveed, adopted EH Medical Policy	Products Affected	11/13/19

Last Res. November 13th, 2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.



Last Res. November 13th, 2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.